MedTrace Logo

NPQ Plus Supplementation for Skin Health and Antioxidant Status

NCT07703215 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2026-07-14

No results posted yet for this study

Summary

This study evaluated the effects of NPQ Plus supplementation on skin health, antioxidant status, fatigue, and self-perceived well-being in healthy adults with skin concerns. NPQ Plus is a multi-component nutraceutical formulation containing polyphenols (Oligonol®), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex), which are known to possess antioxidant and cellular protective properties.

This was a single-arm, open-label, prospective interventional study involving 55 participants. Subjects consumed one sachet of NPQ Plus daily for 12 weeks. Assessments were performed at baseline and at Weeks 4, 8, and 12. Skin health was evaluated using the Patient-Oriented Eczema Measure (POEM), visual analogue scale (VAS), and objective skin biophysical measurements including skin elasticity, hydration, transepidermal water loss (TEWL), pigmentation, inflammation, and sebum secretion. Antioxidant status was assessed by measuring total antioxidant capacity (TAOC), malondialdehyde (MDA), 3-nitrotyrosine (3-NT), and 8-hydroxy-2'-deoxyguanosine (8-OHdG). Fatigue symptoms and self-perceived improvements in skin health, sleep quality, and overall well-being were also evaluated.

Conditions

Interventions

DIETARY_SUPPLEMENT

NPQ Plus

NPQ Plus is a dietary supplement containing Oligonol® (polyphenols), nicotinamide mononucleotide (NMN; RevAge®), pyrroloquinoline quinone (PQQ; PureQQ®), coenzyme Q10 (CoQ10), and a trace mineral complex (Ioniplex). Participants consumed one sachet orally once daily for 12 weeks.

Sponsors & Collaborators

  • UCSI University

    collaborator OTHER

  • JScience Consultancy PLT

    collaborator UNKNOWN

  • N REMEDIER (M) SDN BHD

    lead INDUSTRY

Principal Investigators

  • Chung Keat Tan, PhD · UCSI University

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-04-30
Completion
2026-04-30

Countries

  • Malaysia

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07703215 on ClinicalTrials.gov